论文部分内容阅读
目的 评价西尼地平和氨氯地平降压的疗效和安全性。方法 采用随机双盲双模拟研究方法。西尼地平组 (A组 ) 2 7例 ,氨氯地平组 (B组 ) 2 7例。起始剂量为 5mg ,活性药物治疗 4周后未达到有效标准则药物剂量加倍继续治疗 4周 ,有效者原药量继续服用 4周。总疗程为 8周。结果 两组患者治疗 4周和 8周血压均比用药前下降 (P <0 .0 5 )。A、B两组总有效率分别为 85 .1 9%和 88.89%。两组间总有效率无显著性差异 (P >0 .0 5 )。A、B两组不良反应发生率分别为 1 1 .1 1 %和 1 4 .81 % ,试验过程中不良反应均能耐受 ,无一例退出试验。结论 西尼地平和氨氯地平均是治疗轻、中度高血压的有效药物 ,药物不良反应少
Objective To evaluate the efficacy and safety of cilnidipine and amlodipine in lowering blood pressure. Methods A double-blind, double-dummy study was used. 27 in the cilnidipine group (group A) and 27 in the amlodipine group (group B). The initial dose of 5mg, after 4 weeks of active drug treatment did not meet the effective standard, the drug dose doubling continued treatment for 4 weeks, the effective dose of the original drug continue to take 4 weeks. The total course of treatment is 8 weeks. Results The blood pressure of the two groups was lower at 4 weeks and 8 weeks than before treatment (P <0.05). The total effective rates of A and B groups were 85.119% and 88.89% respectively. The total effective rate between the two groups showed no significant difference (P> 0.05). The incidence of adverse reactions in groups A and B were 11.1% and 14.81%, respectively. All the adverse reactions were tolerated in the course of the trial, and none of them exited the trial. Conclusion Both cilnidipine and amlodipine are effective drugs for the treatment of mild to moderate hypertension with less adverse drug reactions